Skip to main content

Research Repository

See what's under the surface


Leukaemic and Bone Marrow Stromal Cells Alter Cytarabine Genotoxicity and Cytotoxicity in Favour of Disease (2019)
Journal Article
May, J., Gynn, L., Anderson, E., & Robinson, G. (2019). Leukaemic and Bone Marrow Stromal Cells Alter Cytarabine Genotoxicity and Cytotoxicity in Favour of Disease. Mutagenesis, 34(5/6), e5. https://doi.org/10.1093/mutage/gez025

Resistance to therapy remains one of the greatest challenges in the management of the blood and bone marrow (BM) disorder, acute myeloid leukaemia (AML). This study aimed to investigate how leukaemic and BM stromal cells contribute to altered chemo-s... Read More about Leukaemic and Bone Marrow Stromal Cells Alter Cytarabine Genotoxicity and Cytotoxicity in Favour of Disease.

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML). (2019)
Journal Article
Gynn, L. E., Anderson, E., Robinson, G. M., Wexler, S. A., Upstill-Goddard, G., Cox, C., …Morgan, R. G. (2019). Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML). Blood, 134(Supplement 1), 2492. https://doi.org/10.1182/blood-2019-122891

Mesenchymal stromal cells (MSC) are known to protect leukemic cells from drug-induced toxicity within the bone marrow (BM) niche, however, less is known about leukemic impact on supportive MSC. The nucleoside-analogue, cytarabine (Ara-C), is a front-... Read More about Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)..

Intracellular cytarabine triphosphate in circulating blasts post-treatment predicts remission status in patients with acute myeloid leukemia (2019)
Journal Article
Anderson, E., Rees, B., Hull, J., Heywood, J., Preston, A., Protheroe, R., …Mehta, P. (2019). Intracellular cytarabine triphosphate in circulating blasts post-treatment predicts remission status in patients with acute myeloid leukemia. Experimental Hematology, 74, 13-18.e3. https://doi.org/10.1016/j.exphem.2019.04.005

© 2019 Cytarabine remains the backbone of therapy in acute myeloid leukemia (AML). The ability to assess intracellular cytarabine triphosphate (ara-CTP) levels in patients receiving cytarabine represents a major goal in the prediction of treatment re... Read More about Intracellular cytarabine triphosphate in circulating blasts post-treatment predicts remission status in patients with acute myeloid leukemia.

CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML (2018)
Journal Article
Anderson, E., Mehta, P., Heywood, J., Rees, B., Bone, H., Robinson, G., …Mayer, L. (2018). CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML. Leukemia Research, 74, 121-129. https://doi.org/10.1016/j.leukres.2018.08.007

© 2018 Elsevier Ltd CPX-351, a liposomal formulation co-encapsulating cytarabine and daunorubicin (DNR) in a synergistic 5:1 M ratio, has shown favourable response in newly diagnosed elderly high-risk AML. This study assessed intracellular ara-CTP le... Read More about CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.

Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia (2017)
Journal Article
May, J., Steven, J., Taylor, A., Dean, S., & Anderson, E. (2017). Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia. Mutagenesis, 32(6), 627. https://doi.org/10.1093/mutage/gex033

Treatment success in leukaemia is impacted by patient resistance to chemotherapy including cytarabine (ara-C) and the anthracycline daunorubicin (DNR) requiring rapid pre-screening testing. DNR is converted to daunorubicinol (DNRol) by carbonyl reduc... Read More about Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia.

Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor (2017)
Journal Article
Gynn, L., May, J., Anderson, E., & Robinson, G. (2017). Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor. Mutagenesis, 32(6), 619. https://doi.org/10.1093/mutage/gex033

This study aimed to develop a 2D leukaemia-stroma model of the bone marrow for analysis of stromal-mediated chemo-protection; known to contribute to chemotherapy resistance. The model must facilitate integration of a bioluminescent biosensor HA1 for... Read More about Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor.

A novel biosensor for prediction of global hypomethylation by decitabine and azacytadine in leukaemic cells (2015)
Journal Article
May, J. E., Allainguillaume, J., Page, K., Stratford-Smith, C., Aruomaren, A., Alloush, H., …Anderson, E. (2015). A novel biosensor for prediction of global hypomethylation by decitabine and azacytadine in leukaemic cells. Mutagenesis, 30(6), 856. https://doi.org/10.1093/mutage/gev074

Decitabine (DAC) and azacytidine (AZA) are cytidine ana- logues and hypomethylating agents used in the manage- ment of patients with myelodysplastic syndrome (MDS), where the main goal is to prevent transformation to acute myeloid leukaemia (AML), wh... Read More about A novel biosensor for prediction of global hypomethylation by decitabine and azacytadine in leukaemic cells.

Investigation and verification of a bioluminescent biosensor for the quantitation of ara-CTP generation: A biomarker for cytosine arabinoside sensitivity in acute myeloid leukaemia (2014)
Journal Article
Graham Smith, J., Peter Fitzgerald, S., Martin, A., Ann Smith, M., Conway, M., Anderson, E., …Salisbury, V. (2014). Investigation and verification of a bioluminescent biosensor for the quantitation of ara-CTP generation: A biomarker for cytosine arabinoside sensitivity in acute myeloid leukaemia. Biosensors and Bioelectronics, 52, 345-353. https://doi.org/10.1016/j.bios.2013.09.014

A novel whole cell bacterial biosensor, which emits light in response to the active metabolite of cytosine arabinoside (ara-C, cytarabine), ara-CTP, has been investigated and verified. The biosensor has been formulated as an ex vivo assay, designed f... Read More about Investigation and verification of a bioluminescent biosensor for the quantitation of ara-CTP generation: A biomarker for cytosine arabinoside sensitivity in acute myeloid leukaemia.

Effects of bone marrow stromal cells on sensitivity of leukaemic cells to chemotherapy (2013)
Journal Article
Page, K., Anderson, E., Smith, A., Reid, C., Salisbury, V., Donaldson, C., & May, J. E. (2014). Effects of bone marrow stromal cells on sensitivity of leukaemic cells to chemotherapy. Mutagenesis, 29(1), 92. https://doi.org/10.1093/mutage/get060

Cytosine arabinoside (ara-C) is a key chemotherapy drug used to treat acute myeloid leukaemia (AML), however, ap- proximately 30% of patients do not respond to this therapy. 92 An evaluative assay to determine resistance/sensitivity to ara- C prior... Read More about Effects of bone marrow stromal cells on sensitivity of leukaemic cells to chemotherapy.

A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines (2013)
Journal Article
Conway, M., Anderson, E., Smith, M. A., Martin, A., Ruddock, M., Lamont, J., …Salisbury, V. (2013). A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines. Leukemia Research, 37(6), 690-696. https://doi.org/10.1016/j.leukres.2013.02.012

This study evaluates an in vitro biosensor assay capable of detecting the intracellular levels of the tri-phosphorylated form of cytarabine (Ara-CTP) within one working day. The biosensor predicted the response of seven leukaemic cell lines with vary... Read More about A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines.

Detection of intracellular ara-C/ara-CTP following treatment with the new anti-leukemic drug elacytarabine using a bioluminescent bacterial biosensor (2013)
Presentation / Conference
Robinson, G. M., Anderson, E., Salisbury, V., Mehta, P., Sandvold, M., & Reynolds, D. M. (2013, April). Detection of intracellular ara-C/ara-CTP following treatment with the new anti-leukemic drug elacytarabine using a bioluminescent bacterial biosensor. Poster presented at American Association for Cancer Research Annual Meeting

Cytarabine (ara-C) is an analogue of deoxycytidine with an established role in treating AML. Cytarabine depends on the human equilibrative nucleoside transporter-1 (hENT-1) for cellular entry (1). Loss of hENT-1 function in vitro has been shown to re... Read More about Detection of intracellular ara-C/ara-CTP following treatment with the new anti-leukemic drug elacytarabine using a bioluminescent bacterial biosensor.

A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia (2010)
Journal Article
Salisbury, V. C., Hill, P. J., Angell, J. E., Ruddock, M. W., Martin, A. D., Alloush, H. M., …Salisbury, V. (2010). A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia. Clinical Chemistry, 56(12), 1862-1870. https://doi.org/10.1373/clinchem.2010.145581

BACKGROUND: The nucleoside analog cytarabine (Ara-C [cytosine arabinoside]) is the key agent for treating acute myeloid leukemia (AML); however, up to 30% of patients fail to respond to treatment. Screening of patient blood samples to determine drug... Read More about A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia.

The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1 (2009)
Journal Article
Plant, K., Anderson, E., Simecek, N., Brown, R., Forster, S., Spinks, J., …Plant, N. (2009). The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicology and Applied Pharmacology, 235(1), 124-134. https://doi.org/10.1016/j.taap.2008.10.019

The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1 (2009)
Journal Article
Plant, K. E., Anderson, E., Simecek, N., Brown, R., Forster, S., Spinks, J., …Plant, N. (2009). The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicology and Applied Pharmacology, 235(1), 124-134. https://doi.org/10.1016/j.taap.2008.10.019

The mood stabilizing agents lithium chloride (LiCl) and sodium valproate (VPA) have recently gained interest as potential neuroprotective therapeutics. However, exploitation of these therapeutic applications is hindered by both a lack of molecular un... Read More about The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1.

Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: A comparative study involving results from laboratories in 21 countries (2002)
Journal Article
Rhodes, A., Jasani, B., Anderson, E., Dodson, A. R., & Balaton, A. J. (2002). Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: A comparative study involving results from laboratories in 21 countries. American Journal of Clinical Pathology, 118(3), 408-417. https://doi.org/10.1309/97WN-W6UX-XJWT-02H2

Variation in assay sensitivity was studied in more than 90 laboratories that assayed 4formalin-fixed, paraffin-processed breast and ovarian carcinoma cell lines with graded levels of HER-2/neu protein overexpression and known levels of HER-2/neu gene... Read More about Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: A comparative study involving results from laboratories in 21 countries.